MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-01-2023
Seagen DSO Ratio 2011-2026 | SGEN
Annual DSO Ratio Seagen
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 82.9 | 82.8 | 47.1 | 94 | 81.6 | 64.2 | 54.1 | 57.4 | 50 | 40.8 | 59.4 | 214 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 214 | 40.8 | 77.3 |
Quarterly DSO Ratio Seagen
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 85.6 | 81.7 | 87.6 | - | 43.5 | 36.8 | 84.5 | - | 82.5 | 84 | 90.8 | 49.3 | 27.9 | 107 | 109 | 74.3 | 101 | 98.6 | 89.3 | 76.5 | 78.8 | 78.4 | 75 | 59.7 | 57.2 | 71.5 | 61.3 | 53.7 | 53.1 | 59.2 | 47.1 | 51.7 | 57.5 | 62.6 | 51.2 | 48.2 | 47.2 | 52.4 | 46 | 39.9 | 37.9 | 36.6 | 50.1 | 47.8 | 61.2 | 62.5 | 83.6 | 103 | 243 | 384 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 384 | 27.9 | 76.5 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbCellera Biologics
ABCL
|
173 | $ 3.56 | - | $ 1.06 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
AC Immune SA
ACIU
|
22.1 | $ 3.13 | - | $ 229 M |  Schweiz |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Aptorum Group Limited
APM
|
20.6 | $ 0.79 | 0.01 % | $ 4.31 M | China |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
222 | - | - | $ 86.2 M | USA |
 |
Ascendis Pharma A/S
ASND
|
132 | $ 231.03 | 2.23 % | $ 5 B |  Danmark |
 |
Alterity Therapeutics Limited
ATHE
|
16.2 K | $ 3.61 | - | $ 8.69 B |  Australia |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
21.2 | $ 6.63 | - | $ 182 M |  Israel |
 |
BioCardia
BCDA
|
101 | $ 1.27 | - | $ 26.9 M | USA |
 |
Athersys
ATHX
|
22.6 | - | 3.77 % | $ 22.4 M | USA |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M | Canada |
 |
Catalyst Biosciences
CBIO
|
79.3 | $ 11.58 | - | $ 1.03 B | USA |
 |
Cerus Corporation
CERS
|
47 | $ 1.8 | 6.51 % | $ 343 M | USA |
 |
Anika Therapeutics
ANIK
|
77.3 | $ 14.36 | - | $ 210 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
47.5 | - | - | $ 521 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
150 | $ 2.64 | - | $ 16.6 M | USA |
 |
Cardiff Oncology
CRDF
|
294 | $ 1.9 | - | $ 127 M | USA |
 |
CorMedix
CRMD
|
130 | $ 6.54 | - | $ 471 K | USA |